Amedisys (NASDAQ:AMED) Receives Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Amedisys (NASDAQ:AMED) in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a $101.00 price objective on the health services provider’s stock.

A number of other brokerages have also recently issued reports on AMED. Raymond James restated a market perform rating on shares of Amedisys in a research report on Tuesday, March 26th. Royal Bank of Canada lifted their target price on shares of Amedisys from $97.00 to $100.00 and gave the stock an outperform rating in a research report on Monday, March 25th. Finally, StockNews.com started coverage on shares of Amedisys in a research report on Monday, April 8th. They issued a buy rating for the company. Seven analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Hold and a consensus target price of $97.50.

Amedisys Stock Up 0.1 %

Shares of NASDAQ:AMED opened at $91.16 on Thursday. The company has a market cap of $2.98 billion, a price-to-earnings ratio of -294.06, a PEG ratio of 4.29 and a beta of 0.86. The firm’s 50-day simple moving average is $92.57 and its 200-day simple moving average is $93.35. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 0.32. Amedisys has a fifty-two week low of $73.10 and a fifty-two week high of $96.44.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. Amedisys had a negative net margin of 0.44% and a positive return on equity of 12.76%. The firm’s revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.00 earnings per share. As a group, equities research analysts predict that Amedisys will post 4.54 earnings per share for the current year.

Institutional Investors Weigh In On Amedisys

Institutional investors have recently bought and sold shares of the stock. Banque Cantonale Vaudoise purchased a new stake in Amedisys in the first quarter valued at approximately $60,000. Cetera Trust Company N.A purchased a new stake in Amedisys during the fourth quarter worth approximately $215,000. CWM LLC grew its stake in Amedisys by 40.4% during the fourth quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock worth $250,000 after buying an additional 757 shares during the period. Contravisory Investment Management Inc. purchased a new stake in Amedisys during the fourth quarter worth approximately $258,000. Finally, Mesirow Institutional Investment Management Inc. grew its stake in Amedisys by 9.9% during the fourth quarter. Mesirow Institutional Investment Management Inc. now owns 2,844 shares of the health services provider’s stock worth $270,000 after buying an additional 257 shares during the period. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.